Tscan therapeutics announces first patient dosed in phase 1 clinical trial evaluating tcr-t therapy for the treatment of solid tumors

Patient dosed with tsc-20 3 -a0201 targeting cancer-associated antigen prame on-track to report initial data from the solid tumor clinical trial in 2024 waltham, mass., may 09, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell (tcr-t) therapies for the treatment of patients with cancer, today announced that the first patient has been dosed in the company's phase 1 trial evaluating tcr-t therapy for the treatment of solid tumors.
TCRX Ratings Summary
TCRX Quant Ranking